Levetiracetam use and pregnancy outcome

Prenatal exposure to levetiracetam (LEV) has been shown to cause skeletal abnormalities and growth retardation in animal studies, but the teratogenicity of this new antiepileptic drug in humans is still unknown. We detected no malformations in a series of I I pregnancies with LEV exposure, although it was striking that three cases had a low birth weight. There may be an association between maternal LEV use and reduced birth weight. but too few cases have been monitored so far. We recommend that the outcomes of all pregnancies exposed to LEV should be carefully registered. (c) 2004 Elsevier Inc. All rights reserved.